175 related articles for article (PubMed ID: 3742834)
1. Discordant responses of prolactinoma to two different dopamine agonists.
Ahmed SR; Shalet SM
Clin Endocrinol (Oxf); 1986 Apr; 24(4):421-6. PubMed ID: 3742834
[TBL] [Abstract][Full Text] [Related]
2. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
Johnston DG; Hall K; Kendall-Taylor P; Patrick D; Watson M; Cook DB
Lancet; 1984 Jul; 2(8396):187-92. PubMed ID: 6146751
[TBL] [Abstract][Full Text] [Related]
3. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.
Horowitz BL; Hamilton DJ; Sommers CJ; Bryan RN; Boyd AE
AJNR Am J Neuroradiol; 1983; 4(3):415-7. PubMed ID: 6410759
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
5. The effect of dopamine agonist therapy on large functionless pituitary tumours.
Grossman A; Ross R; Charlesworth M; Adams CB; Wass JA; Doniach I; Besser GM
Clin Endocrinol (Oxf); 1985 May; 22(5):679-86. PubMed ID: 4028461
[TBL] [Abstract][Full Text] [Related]
6. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.
Breidahl HD; Topliss DJ; Pike JW
Br Med J (Clin Res Ed); 1983 Aug; 287(6390):451-2. PubMed ID: 6411170
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1177-9. PubMed ID: 6404378
[TBL] [Abstract][Full Text] [Related]
8. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic resistance in prolactinoma patients.
Molitch ME
Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy after bromocriptine-induced reduction of an extrasellar prolactin-secreting pituitary macroadenoma.
Goodman LA; Chang RJ
Obstet Gynecol; 1984 Sep; 64(3 Suppl):2S-7S. PubMed ID: 6433250
[TBL] [Abstract][Full Text] [Related]
11. Bromocriptine reduction of prolactinoma size.
Corenblum B; Hanley DA
Fertil Steril; 1981 Dec; 36(6):716-9. PubMed ID: 7308514
[TBL] [Abstract][Full Text] [Related]
12. The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography.
Johnston DG; Hall K; Kendall-Taylor P; Ross WM; Crombie AL; Cook DB; Watson MJ
Clin Endocrinol (Oxf); 1986 Jun; 24(6):675-85. PubMed ID: 3098457
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine.
Zárate A; Canales ES; Cano C; Pilonieta CJ
Acta Endocrinol (Copenh); 1983 Oct; 104(2):139-42. PubMed ID: 6356741
[TBL] [Abstract][Full Text] [Related]
14. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
16. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study.
Blackwell RE; Bradley EL; Kline LB; Duvall ER; Vitek JJ; DeVane GW; Chang RJ
Fertil Steril; 1983 Jun; 39(6):744-8. PubMed ID: 6343127
[TBL] [Abstract][Full Text] [Related]
18. Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report.
Clayton RN; Webb J; Heath DA; Dunn PJ; Rolfe EB; Hockley AD
Clin Endocrinol (Oxf); 1985 May; 22(5):573-81. PubMed ID: 4028456
[TBL] [Abstract][Full Text] [Related]
19. Dopamine resistance of prolactinomas.
Molitch ME
Pituitary; 2003; 6(1):19-27. PubMed ID: 14674720
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.
Grossman A; Bouloux PM; Loneragan R; Rees LH; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1985 May; 22(5):611-6. PubMed ID: 4028459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
